Q1 2016 · —
Revenue$336.01M$336.01M +8.6% vs Q1 2015−1.4% vs Q4 2015
Net Income$75.81M$75.81M +7.2% vs Q1 2015−8.4% vs Q4 2015
EPS Diluted$1.21$1.21 +8.0% vs Q1 2015−8.3% vs Q4 2015
Gross Profit$310,477,000+11.4%
Operating Income$121,162,000+3.8%
Operating Cash Flow$151,654,000+57.1%
Free Cash Flowderived$149,182,000+81.6%
Margins · derived
Gross margin92.4%+2.3 pt vs Q1 2015
Operating margin36.1%−1.7 pt vs Q1 2015
Net margin22.6%−0.3 pt vs Q1 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2016 | Q1 2015 | Q1 2014 | Q1 2013 |
|---|---|---|---|---|
| Revenue | $336.01M | $309.30M | $246.92M | $196.24M |
| Net Income | $75.81M | $70.70M | -$92.65M | $43.43M |
| EPS Diluted | $1.21 | $1.12 | -$1.58 | $0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR